Plaintiff

Avadel CNS Pharmaceuticals, LLC

9 cases as plaintiff.

Cases
9
Active
3
6 closed
Filed
2022–2026
Top venue
D. Delaware
2 cases
Also appears as a defendant in 9 cases → View as defendant

Company profile

Avadel CNS Pharmaceuticals, LLC is a Delaware limited liability company and a wholly owned subsidiary of Avadel US Holdings, Inc., which is in turn wholly owned by Avadel Pharmaceuticals plc (Nasdaq: AVDL), an Irish public limited company. Its U.S. principal place of business is 16640 Chesterfield Grove Road, Chesterfield, Missouri; the parent is headquartered in Dublin, Ireland. Avadel plc was incorporated in Ireland in December 2015 as successor to Flamel Technologies (founded 1990) and took its current name in January 2017. Per its FY2024 Form 10-K, Avadel plc reported approximately 188 employees and $169.1 million in net product revenue, with a net loss of $48.8 million; market capitalization was reported near $1.4 billion in 2024.

Avadel CNS is the entity holding and developing the company's narcolepsy franchise. Its sole commercial product is LUMRYZ (sodium oxybate), an extended-release, once-nightly formulation approved by the FDA in May 2023 for cataplexy or excessive daytime sleepiness in adults with narcolepsy, and in October 2024 for patients aged seven and older. LUMRYZ uses the parent's proprietary Micropump drug-delivery technology, is dispensed through a restricted REMS distribution program, and is sold to specialty pharmacies. The parent previously marketed hospital injectables but has since refocused on sleep medicine. This is an operating company, not a patent assertion entity.

Litigation posture: Avadel CNS is an active two-way litigant — 9 tracked plaintiff cases and 9 defendant cases — dominated by Hatch-Waxman/Orange Book disputes rather than NPE-style assertion. Venues are the District of Delaware, the District of Columbia, the District of New Jersey, and the Federal Circuit; no Eastern District of Texas filings appear in the tracked data.

Notable matters: Jazz Pharmaceuticals sued Avadel CNS repeatedly (2021–2022) over sodium oxybate patents, including a REMS-distribution patent later delisted from the Orange Book; a February 2024 Delaware jury awarded Jazz roughly $233,562.83 on one process patent. Avadel CNS counterclaimed with Sherman Act claims over the Orange Book listing and filed its own infringement suits against Jazz in 2023 and 2025. Avadel also sued HHS Secretary Becerra in D.D.C. (2022) over its FDA application, and in July 2026 filed against Granules India Limited in New Jersey. The parties announced a global settlement in October 2025.

Keep this research.

Save to your free workspace, then choose whether to receive updates.

Filing activity

2022: 6 cases6'222023: 1 case'23'24'252026: 1 case'26
Cases filed per year with Avadel CNS Pharmaceuticals, LLC as plaintiff.

Avadel CNS Pharmaceuticals, LLC v. Xavier Becerra et al.

denied Avadel's requested relief
Docket:
1:22-cv-02159
Filed:
2022-07-21
Patents:8731963

APA challenge to FDA's requirement that Avadel certify against U.S. 8,731,963 (REMS patent). Jazz Pharmaceuticals intervened on July 28, 2022, to defend the FDA decision. The D.D.C. denied Avadel's requested relief, holding Avadel had an adequate remedy at law via its delisting counterclaim in the Delaware action.

Avadel CNS Pharmaceuticals, LLC et al. v. Jazz Pharmaceuticals, Inc. et al.

dismissed with prejudice (settled)
Docket:
1:22-cv-00487-GBW
Filed:
2022-04-14
Terminated:
2025-10-27
Patents:10758488

Avadel's action against Jazz alleging breach of confidentiality agreements, trade-secret misappropriation, correction of inventorship under 35 U.S.C. § 256, and antitrust counterclaims, relating to subject matter Avadel alleges Jazz copied into its patents including the '488 patent. Jazz's motion to dismiss and motions to stay were denied. Resolved by the October 2025 global settlement and dismissed with prejudice.

Avadel CNS Pharmaceuticals, LLC et al. v. Jazz Pharmaceuticals, Inc. et al.

dismissed with prejudice (settled)
Docket:
1:22-cv-00487-GBW
Filed:
2022-04-14
Terminated:
2025-10-27
Patents:11147782

Avadel's affirmative trade-secrets and inventorship action; Avadel alleged Jazz used confidential information and sought correction of inventorship of certain Jazz patents, including the '782 patent. Dismissed with prejudice on October 27, 2025 pursuant to settlement.

Avadel CNS Pharmaceuticals, LLC et al. v. Jazz Pharmaceuticals, Inc. et al.

dismissed
Docket:
1:22-cv-00487-GBW
Filed:
2022-04-14
Terminated:
2025-10-27

Avadel-side Delaware action in which Flamel/Avadel asserted their modified-release GHB patent family, including U.S. 10,272,062 and 10,736,866 (parents of the '986 patent) and U.S. 10,952,986, against Jazz. The case was consolidated and dismissed by order on 2025-10-27 as part of the settlement.

Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc.

settled
Docket:
1:22-cv-00487
Filed:
2022-04-14
Terminated:
2025-10-27
Patents:10864181

Avadel CNS Pharmaceuticals, LLC filed a case against Jazz Pharmaceuticals, Inc. in the District of Delaware. It was part of the global Jazz-Avadel dispute and was settled in October 2025, with District of Delaware cases terminated 2025-10-27.

Avadel CNS Pharmaceuticals, LLC v. Jazz Pharmaceuticals, Inc. et al.

decided; reversed-in-part, vacated-in-part, remanded
Docket:
2024-2274, 2024-2277, 2024-2278
Terminated:
2025-05-06
Patents:11147782

Consolidated Federal Circuit appeal from D. Del. Nos. 1:21-cv-00691-GBW, 1:21-cv-01138-GBW, and 1:21-cv-01594-GBW concerning the permanent injunction in the '782 patent dispute. The Federal Circuit reversed-in-part, vacated-in-part, and remanded on May 6, 2025.